secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2022-02-28T23:59:59+00:00
Accession:  0001193125-22-057853
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus appoints Mark Singleton as CFO effective March 21, 2022, succeeding Gregory Anglum
--------------------------------------------------------------------------------

- Mark Singleton appointed CFO, effective March 21, 2022; joins from Teleflex Inc.
- Base salary of $430,000, annual bonus target 50% of base salary.
- Initial equity grants: 74,500 RSUs and options for 223,200 shares, vesting over 4 years.
- Cash buyout of unvested Teleflex equity of $81,943; plus sign-on cash for unpaid 2021 bonus.
- Former CFO Gregory Anglum to remain through April 2022 to assist transition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000119312522057853/0001193125-22-057853-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000119312522057853/d151986d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-057853

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer